Faron Pharmaceuticals Oy (FARN)

Currency in GBP
41.50
0.00(0.00%)
Closed·
FARN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
40.0042.56
52 wk Range
38.00270.00
Key Statistics
Bid/Ask
40.00 / 45.00
Prev. Close
41.5
Open
41.5
Day's Range
40-42.56
52 wk Range
38-270
Volume
7.03K
Average Volume (3m)
238.04K
1-Year Change
-78.4416%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
FARN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
998.27
Upside
+2,305.48%
Members' Sentiments
Bearish
Bullish
ProTips
Stock generally trades with high price volatility

Faron Pharmaceuticals Oy News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 998.27
(+2,305.48% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Aug 27, 2025
EPS / Forecast
-0.18 / -0.13
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

FARN Income Statement

Compare FARN to Peers and Sector

Metrics to compare
FARN
Peers
Sector
Relationship
P/E Ratio
−3.5x−2.6x−0.5x
PEG Ratio
−0.210.000.00
Price/Book
−5.2x0.8x2.6x
Price / LTM Sales
-7.3x3.2x
Upside (Analyst Target)
-105.3%48.1%
Fair Value Upside
Unlock−0.8%6.6%Unlock

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company’s lead product candidate is Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. It is also developing bexmarilimab for the treatment of hematological and solid tumor cancers; and in combination with care therapies, azacitidine, and other hypomethylating agents in relapsed/refractory myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. In addition, the company develops receptors involved in regulation of immune response in organ damage and bone marrow regeneration. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
2.98M1.49%1.24M
Other Institutional Investors
61.98M31.07%25.72M
Public Companies & Retail Investors
134.55M67.44%55.84M
Total
199.51M100.00%82.8M

People Also Watch

0.2550
ECRE
+4.08%
3.125
GWMO
+5.93%
1.10
BLOE
+2.79%
12,040.0
GDWN
+4.51%
0.26
PYX
0.00%

FAQ

What Is the Faron Pharmaceuticals Oy (FARN) Stock Price Today?

The Faron Pharmaceuticals Oy stock price today is 41.50 GBP.

What Stock Exchange Does Faron Pharmaceuticals Oy Trade On?

Faron Pharmaceuticals Oy is listed and trades on the London Stock Exchange.

What Is the Stock Symbol for Faron Pharmaceuticals Oy?

The stock symbol for Faron Pharmaceuticals Oy is "FARN."

What Is the Faron Pharmaceuticals Oy Market Cap?

As of today, Faron Pharmaceuticals Oy market cap is 82.80M GBP.

What Is Faron Pharmaceuticals Oy's Earnings Per Share (TTM)?

The Faron Pharmaceuticals Oy EPS (TTM) is -0.24.

From a Technical Analysis Perspective, Is FARN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Faron Pharmaceuticals Oy Stock Split?

Faron Pharmaceuticals Oy has split 1 times.

How Many Employees Does Faron Pharmaceuticals Oy Have?

Faron Pharmaceuticals Oy has 33 employees.

What is the current trading status of Faron Pharmaceuticals Oy (FARN)?

As of May 03, 2026, Faron Pharmaceuticals Oy (FARN) is trading at a price of 41.50 GBP, with a previous close of 41.50 GBP. The stock has fluctuated within a day range of 40.00 GBP to 42.56 GBP, while its 52-week range spans from 38.00 GBP to 270.00 GBP.

What Is Faron Pharmaceuticals Oy (FARN) Price Target According to Analysts?

The average 12-month price target for Faron Pharmaceuticals Oy is 998.27 GBP, with a high estimate of 998.27482101 GBP and a low estimate of 998.27482101 GBP. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +2,305.48% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.